About talquetam ab
Bispecific GPRC5D-directed CD3 T-cell engager
Used for
- Treats adults with relapsed or refractory multiple myeloma after several previous treatments.
Usual adult dose
Given by injection under the skin, starting with step-up doses. Maintenance is usually weekly or every two weeks; dosing depends on treatment phase and local prescribing information.
Common side effects
- Cytokine release syndrome, including fever and low blood pressure
- Infections, low blood-cell counts, and fatigue
- Taste changes, dry mouth, and weight loss
- Nerve problems, including confusion or difficulty speaking
Important warnings
- Can cause serious or fatal cytokine release syndrome and neurologic toxicity; initial doses require close monitoring.
- Serious infections and low blood counts can occur.
- May cause severe skin and nail reactions, and oral or swallowing problems.
- Can harm an unborn baby; effective contraception is required during treatment and for three months afterward.
Pregnancy
May cause fetal harm. Pregnancy status is checked before treatment; effective contraception is advised during treatment and for three months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for three months after the last dose.
Interactions
- No specific major drug interactions are established; tell the treatment team about all medicines and supplements.
- May affect the reliability of some tests that measure antibodies or other immune proteins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.